Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

被引：11

作者：

Bar, Noffar ^{[1
,2
]}

Victoria Mateos, Maria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
,6
]}

Paris, Laura ^{[7
]}

Hofmeister, Craig C. ^{[8
]}

Rodriguez Otero, Paula ^{[9
]}

Aranzazu Bermudez, Maria ^{[10
]}

Martin, Thomas ^{[11
]}

Santoro, Armando ^{[12
,13
]}

Yee, Andrew J. ^{[14
]}

Creignou, Maria ^{[15
]}

Encinas Rodriguez, Cristina ^{[16
]}

Cerchione, Claudio ^{[17
]}

De La Rubia, Javier ^{[18
]}

Oriol, Albert ^{[19
,20
]}

Waibel, Heidi ^{[21
]}

Besemer, Britta ^{[22
]}

Thompson, Ethan ^{[23
]}

Kiesel, Brian ^{[23
]}

Chen, Jinjie ^{[23
]}

Chung, Alexander ^{[23
]}

Boss, Isaac W. ^{[23
]}

Gaudy, Allison ^{[23
]}

Li, Shaoyi ^{[23
]}

Hsu, Kevin ^{[23
]}

Godwin, Colin ^{[23
]}

Burgess, Michael R. ^{[23
]}

San-Miguel, Jesus ^{[9
]}

Costa, Luciano ^{[24
]}

机构：

[1] Yale Univ, Dept Internal Med, Sect Hematol, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] Sahlgrens Univ Hosp, Gothenburg, Sweden

[7] ASST Papa Giovanni XXIII, Bergamo, Italy

[8] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA

[9] Canc Ctr Clin Univ Navarra CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[10] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[11] Univ Calif San Francisco, San Francisco, CA USA

[12] Humanitas Univ, Milan, Italy

[13] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[14] Massachusetts Gen Canc Ctr, Boston, MA USA

[15] Karolinska Univ Hosp, Phase 1 Unit, Ctr Clin Canc Studies, Stockholm, Sweden

[16] Hosp Gen Univ Gregorio Maranon, IiSGM, Madrid, Spain

[17] Ist Sci Romagnolo Studio & Cura Tumori IRS IRCCS, Meldola, FC, Italy

[18] Univ Hosp La Fe, Valencia, Spain

[19] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[20] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[21] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[22] Univ Hosp Tuebingen, Tubingen, Germany

[23] Bristol Myers Squibb, Princeton, NJ USA

[24] Univ Alabama Birmingham, Birmingham, AL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[21] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[22] Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Raje, Noopur S.
Jakubowiak, Andrzej
Gasparetto, Cristina
Cornell, Robert F.
Krupka, Heike I.
Navarro, Daniel
Forgie, Alison J.
Udata, Chandrasekhar
Basu, Cynthia
Chou, Jeffrey
Leung, Abraham
Lesokhin, Alexander M.
BLOOD, 2019, 134
[23] Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Zweegman, Sonja
Cavet, Jim
Yong, Kwee
Lee, Lydia
Faulkner, Jim
Kotsopoulou, Ekaterini
Al-Hajj, Muhammad
Thomas, Simon
Cordoba, Shaun P.
Pule, Martin
Cerec, Virginie
Peddareddigari, Vijay G. R.
Khokhar, Nushmia Z.
Menne, Tobias F.
BLOOD, 2019, 134
[24] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[25] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Donk, Van De N. W.
Moreau, P.
Garfall, A. L.
Bhutani, M.
Oriol, A.
Nooka, A. K.
Martin, T. G.
Rosinol, L.
Mateos, M. -V.
Bahlis, N.
Popat, R.
Besemer, B.
Lopez, Martinez J.
Krishnan, A.
Delforge, M.
Trancucci, D.
Verona, R., I
Stephenson, T.
Chastain, K.
Sidana, S.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
[26] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
[27] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy
Dholaria, Bhagirathbhai
Shune, Leyla
Kin, Andrew
McArthur, Katherine
Eskew, Jeff D.
Martin, Christopher E.
Haag, Sabrina
McCaigue, Joanne
Namini, Hamid
DePrimo, Sam
Cranert, Stacey
Coronella, Julia
Shedlock, Devon
Belani, Rajesh
CANCER RESEARCH, 2024, 84 (07)
[30] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin, Alexander M.
Arnulf, Bertrand
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Tomasson, Michael H.
Rodriguez-Otero, Paula
Quach, Hang
Raje, Noopur S.
Iida, Shinsuke
Raab, Marc-Steffen
Czibere, Akos
Sullivan, Sharon
Leip, Eric
Viqueira, Andrea
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →